123 related articles for article (PubMed ID: 34652529)
1. Correction to: Actovegin® reduces PMA‑induced inflammation on human cells.
Reichl FX; Högg C; Liu F; Schwarz M; Teupser D; Hickel R; Bloch W; Schweikl H; Thomas P; Summer B
Eur J Appl Physiol; 2022 Jan; 122(1):267. PubMed ID: 34652529
[No Abstract] [Full Text] [Related]
2. Actovegin® reduces PMA-induced inflammation on human cells.
Reichl FX; Högg C; Liu F; Schwarz M; Teupser D; Hickel R; Bloch W; Schweikl H; Thomas P; Summer B
Eur J Appl Physiol; 2020 Jul; 120(7):1671-1680. PubMed ID: 32447451
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analytics of Actovegin® and Its Effect on Muscle Cells.
Reichl FX; Holdt LM; Teupser D; Schütze G; Metcalfe AJ; Hickel R; Högg C; Bloch W
Int J Sports Med; 2017 Oct; 38(11):809-818. PubMed ID: 28895623
[TBL] [Abstract][Full Text] [Related]
4. Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin
Firan FC; Romila A; Onose G
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365943
[TBL] [Abstract][Full Text] [Related]
5. Our experience on Actovegin, is it cutting edge?
Lee P; Rattenberry A; Connelly S; Nokes L
Int J Sports Med; 2011 Apr; 32(4):237-41. PubMed ID: 21271496
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro.
Elmlinger MW; Kriebel M; Ziegler D
Neuromolecular Med; 2011 Dec; 13(4):266-74. PubMed ID: 21983748
[TBL] [Abstract][Full Text] [Related]
7. [New approaches in the regulation of blood phagocytes and reduction in the formation of oxygen radicals in patients with heart failure].
Astashkin EI; Glezer MG; Vinokurov MG; Orekhova NS; Egorova ND; Novikova aN; Iurinskaia MM; Grachev SV; Sobolev KÉ
Vestn Ross Akad Med Nauk; 2014; (7-8):100-5. PubMed ID: 25563010
[TBL] [Abstract][Full Text] [Related]
8. Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle.
Søndergård SD; Dela F; Helge JW; Larsen S
Eur J Sport Sci; 2016 Oct; 16(7):801-7. PubMed ID: 26744809
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation.
Dieckmann A; Kriebel M; Andriambeloson E; Ziegler D; Elmlinger M
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):132-8. PubMed ID: 22020669
[TBL] [Abstract][Full Text] [Related]
10. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia.
Meilin S; Machicao F; Elmlinger M
J Cell Mol Med; 2014 Aug; 18(8):1623-30. PubMed ID: 24797227
[TBL] [Abstract][Full Text] [Related]
11. [Oral actovegin therapy in cerebrovascular insufficiency. Studies on the therapeutic value of actovegin forte dragees in elderly patients with advanced cerebrovascular insufficiency].
Kopp H
Fortschr Med; 1979 Feb; 97(7):307-12. PubMed ID: 437665
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy.
Ziegler D; Edmundson S; Gurieva I; Mankovsky B; Papanas N; Strokov I
J Diabetes Complications; 2017 Jul; 31(7):1181-1187. PubMed ID: 28438471
[TBL] [Abstract][Full Text] [Related]
13. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
Guekht A; Skoog I; Edmundson S; Zakharov V; Korczyn AD
Stroke; 2017 May; 48(5):1262-1270. PubMed ID: 28432265
[TBL] [Abstract][Full Text] [Related]
14. [Functional improvement of the aging brain: placebo controlled pharmaco-EEG and psychometric studies with a metabolically active hemoderivative (Actovegin)].
Saletu B; Grünberger J; Linzmayer L; Stöhr H
Z Gerontol; 1984; 17(5):271-9. PubMed ID: 6395527
[TBL] [Abstract][Full Text] [Related]
15. No effect of intravenous Actovegin® on peak aerobic capacity.
Lee P; Nokes L; Smith PM
Int J Sports Med; 2012 Apr; 33(4):305-9. PubMed ID: 22318562
[TBL] [Abstract][Full Text] [Related]
16. Update on the Role of Actovegin in Musculoskeletal Medicine: A Review of the Past 10 Years.
Brock J; Golding D; Smith PM; Nokes L; Kwan A; Lee PYF
Clin J Sport Med; 2020 Jan; 30(1):83-90. PubMed ID: 31855916
[TBL] [Abstract][Full Text] [Related]
17. [The measures of autonomic homeostasis as predictors of an individual risk of stroke and their dynamics during therapy with actovegin].
Jakupov EZ; Nalbat AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10 Pt 2):31-42. PubMed ID: 26977914
[TBL] [Abstract][Full Text] [Related]
18. [Stimulation of cell cultures recovery after cryopreservation by the cattle cord blood FRACTION (below 5 kDa) or Actovegin].
Gulevskiĭ AK; Trifonova AV; Lavrik AA
Tsitologiia; 2013; 55(9):619-25. PubMed ID: 25470939
[TBL] [Abstract][Full Text] [Related]
19. [Methods of augmentation of antidepressant therapy (on the model of complex therapy with the inclusion of actovegin) in gerontopsychiatric hospital].
Safarova TP; Yakovleva OB; Sheshenin VS; Gavrilova SI
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(6. Vyp. 2):55-63. PubMed ID: 30346435
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats.
Kurkin DV; Bakulin DA; Morkovin EI; Kalatanova AV; Makarenko IE; Dorotenko AR; Kovalev NS; Dubrovina MA; Verkholyak DV; Abrosimova EE; Smirnov AV; Shmidt MV; Tyurenkov IN
PLoS One; 2021; 16(7):e0254493. PubMed ID: 34260655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
